IMTX Quote, Financials, Valuation and Earnings

BioNTech SE has a net margin of -214.48% compared to Immatics NV's net margin of -227.46%. Immatics NV's return on equity of -4.67% beat BioNTech SE's return on equity of -3.91%.

Immatics NV has a consensus price target of $14.33, signalling upside risk potential of 149.28%. On the other hand BioNTech SE has an analysts' consensus of $133.41 which suggests that it could grow by 20.04%. Given that Immatics NV has higher upside potential than BioNTech SE, analysts believe Immatics NV is more attractive than BioNTech SE.

Immatics NV has a beta of 0.827, which suggesting that the stock is 17.335% less volatile than S&P 500. In comparison BioNTech SE has a beta of 1.288, suggesting its more volatile than the S&P 500 by 28.759%.

Immatics NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioNTech SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immatics NV pays -- of its earnings as a dividend. BioNTech SE pays out -- of its earnings as a dividend.

Immatics NV quarterly revenues are $19.6M, which are smaller than BioNTech SE quarterly revenues of $192.3M. Immatics NV's net income of -$41.9M is higher than BioNTech SE's net income of -$437.5M. Notably, Immatics NV's price-to-earnings ratio is 42.21x while BioNTech SE's PE ratio is 191.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immatics NV is 4.19x versus 9.01x for BioNTech SE. Usually stocks with elevated PS ratios are considered overvalued.

CureVac NV has a net margin of -214.48% compared to Immatics NV's net margin of -5832.47%. Immatics NV's return on equity of -4.67% beat CureVac NV's return on equity of 32.68%.

Immatics NV has a consensus price target of $14.33, signalling upside risk potential of 149.28%. On the other hand CureVac NV has an analysts' consensus of $6.29 which suggests that it could grow by 41.7%. Given that Immatics NV has higher upside potential than CureVac NV, analysts believe Immatics NV is more attractive than CureVac NV.

Immatics NV has a beta of 0.827, which suggesting that the stock is 17.335% less volatile than S&P 500. In comparison CureVac NV has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Immatics NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CureVac NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immatics NV pays -- of its earnings as a dividend. CureVac NV pays out -- of its earnings as a dividend.

Immatics NV quarterly revenues are $19.6M, which are larger than CureVac NV quarterly revenues of $939.6K. Immatics NV's net income of -$41.9M is higher than CureVac NV's net income of -$54.8M. Notably, Immatics NV's price-to-earnings ratio is 42.21x while CureVac NV's PE ratio is 4.92x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immatics NV is 4.19x versus 1.74x for CureVac NV. Usually stocks with elevated PS ratios are considered overvalued.

Evotec SE has a net margin of -214.48% compared to Immatics NV's net margin of -15.79%. Immatics NV's return on equity of -4.67% beat Evotec SE's return on equity of -20.84%.

Immatics NV has a consensus price target of $14.33, signalling upside risk potential of 149.28%. On the other hand Evotec SE has an analysts' consensus of $6.3925 which suggests that it could grow by 59.88%. Given that Immatics NV has higher upside potential than Evotec SE, analysts believe Immatics NV is more attractive than Evotec SE.

Immatics NV has a beta of 0.827, which suggesting that the stock is 17.335% less volatile than S&P 500. In comparison Evotec SE has a beta of 1.656, suggesting its more volatile than the S&P 500 by 65.647%.

Immatics NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Evotec SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immatics NV pays -- of its earnings as a dividend. Evotec SE pays out -- of its earnings as a dividend.

Immatics NV quarterly revenues are $19.6M, which are smaller than Evotec SE quarterly revenues of $210.4M. Immatics NV's net income of -$41.9M is lower than Evotec SE's net income of -$33.2M. Notably, Immatics NV's price-to-earnings ratio is 42.21x while Evotec SE's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immatics NV is 4.19x versus 1.72x for Evotec SE. Usually stocks with elevated PS ratios are considered overvalued.

InflaRx NV has a net margin of -214.48% compared to Immatics NV's net margin of -14092.9%. Immatics NV's return on equity of -4.67% beat InflaRx NV's return on equity of -56.78%.

Immatics NV has a consensus price target of $14.33, signalling upside risk potential of 149.28%. On the other hand InflaRx NV has an analysts' consensus of $3.62 which suggests that it could grow by 325.65%. Given that InflaRx NV has higher upside potential than Immatics NV, analysts believe InflaRx NV is more attractive than Immatics NV.

Immatics NV has a beta of 0.827, which suggesting that the stock is 17.335% less volatile than S&P 500. In comparison InflaRx NV has a beta of 1.287, suggesting its more volatile than the S&P 500 by 28.694%.

Immatics NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InflaRx NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immatics NV pays -- of its earnings as a dividend. InflaRx NV pays out -- of its earnings as a dividend.

Immatics NV quarterly revenues are $19.6M, which are larger than InflaRx NV quarterly revenues of -$450. Immatics NV's net income of -$41.9M is lower than InflaRx NV's net income of -$8.7M. Notably, Immatics NV's price-to-earnings ratio is 42.21x while InflaRx NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immatics NV is 4.19x versus 280.79x for InflaRx NV. Usually stocks with elevated PS ratios are considered overvalued.